Inotodiol ameliorates the progression of osteoarthritis: An in vitro and in vivo study.

IF 2.1 Q3 PHARMACOLOGY & PHARMACY Drug Research Pub Date : 2023-11-01 Epub Date: 2023-11-07 DOI:10.1055/a-2176-4098
Wanfeng Qian, Ruheng Ji, Qiujie Ye, Wenjun Hu, Linying Zhou, Hongwu Pan, Xiaoming Li
{"title":"Inotodiol ameliorates the progression of osteoarthritis: An in vitro and in vivo study.","authors":"Wanfeng Qian, Ruheng Ji, Qiujie Ye, Wenjun Hu, Linying Zhou, Hongwu Pan, Xiaoming Li","doi":"10.1055/a-2176-4098","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoarthritis is a common chronic degenerative disease, of which the essence is the degenerative changes of bone and joint cartilage, involving damage in multiple structures such as bone, synovium and joints. In the mechanism of arthritis inflammation is closely related, and therefore the exploration to inhibit inflammatory mediators is crucial for the clinical prevention and treatment of osteoarthritis. Inotodiol is a lanostane triterpenoid isolated from Inonotus obliquus, which had been extensively reported to be an anti-inflammatory agent, but its effect on arthritis remains unknown. In this study, we firstly demonstrated that inotodiol significantly reduced IL-1β-induced chondrocyte injury and inhibited the release of inflammatory factors. At the same time, experiments <i>in vivo</i> showed that inotodiol could effectively improve the symptoms of joint injury in mice and reduce the area of cartilage destruction, indicating that inotodiol may be a potential therapeutic drug for osteoarthritis.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 9","pages":"506-512"},"PeriodicalIF":2.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2176-4098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Osteoarthritis is a common chronic degenerative disease, of which the essence is the degenerative changes of bone and joint cartilage, involving damage in multiple structures such as bone, synovium and joints. In the mechanism of arthritis inflammation is closely related, and therefore the exploration to inhibit inflammatory mediators is crucial for the clinical prevention and treatment of osteoarthritis. Inotodiol is a lanostane triterpenoid isolated from Inonotus obliquus, which had been extensively reported to be an anti-inflammatory agent, but its effect on arthritis remains unknown. In this study, we firstly demonstrated that inotodiol significantly reduced IL-1β-induced chondrocyte injury and inhibited the release of inflammatory factors. At the same time, experiments in vivo showed that inotodiol could effectively improve the symptoms of joint injury in mice and reduce the area of cartilage destruction, indicating that inotodiol may be a potential therapeutic drug for osteoarthritis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肌醇改善骨关节炎的进展:一项体外和体内研究。
骨关节炎是一种常见的慢性退行性疾病,其本质是骨和关节软骨的退行性变化,涉及骨、滑膜和关节等多个结构的损伤。在关节炎的发病机制中,炎症是密切相关的,因此探索抑制炎症介质对骨关节炎的临床防治至关重要。肌苷醇是从斜孔菌中分离出的羊毛甾烷三萜,已被广泛报道为抗炎剂,但其对关节炎的影响尚不清楚。在本研究中,我们首次证明了inotodiol显著减少了IL-1β诱导的软骨细胞损伤,并抑制了炎症因子的释放。同时,体内实验表明,inotodiol可以有效改善小鼠关节损伤症状,减少软骨破坏面积,表明inotodil可能是治疗骨关节炎的潜在药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Research
Drug Research PHARMACOLOGY & PHARMACY-
CiteScore
3.50
自引率
0.00%
发文量
67
期刊介绍: Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.
期刊最新文献
Synergistic Effects of Curcumin and Temozolomide in Overcoming Glioblastoma Drug Resistance through Regulation of O6-Methylguanine-DNA Methyltransferase, Mismatch Repair, and Poly(Adenosine Diphosphate Ribose) Polymerase 1. Linezolid-Induced Serotonin Release from QGP-1 Cells. Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles. Intramolecular Interactions of Twenty-Eight Amide Derivatives with the C-ALB Kinase using a Theoretical Model as a Therapeutic Alternative to Treat Cancer. Advances in Janus Kinase Inhibitors for Vitiligo Treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1